Sphingosine 1-phosphate (S1P), a lysophospholipid, has gained relevance to multiple sclerosis through the discovery of FTY720 (fingolimod), recently approved as an oral treatment for relapsing forms of multiple sclerosis. Its mechanism of action is thought to be immunological through an active phosphorylated metabolite, FTY720-P, that resembles S1P and alters lymphocyte trafficking through receptor subtype S1P 1 . However, previously reported expression and in vitro studies of S1P receptors suggested that direct CNS effects of FTY720 might theoretically occur through receptor modulation on neurons and glia. To identify CNS cells functionally contributing to FTY720 activity, genetic approaches were combined with cellular and molecular analyses. These studies relied on the functional assessment, based on clinical score, of conditional null mouse mutants lacking S1P 1 in CNS cell lineages and challenged by experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. All conditional null mutants displayed WT lymphocyte trafficking that responded normally to FTY720. In marked contrast, EAE was attenuated and FTY720 efficacy was lost in CNS mutants lacking S1P 1 on GFAP-expressing astrocytes but not on neurons. In situ hybridization studies confirmed that astrocyte loss of S1P 1 was the key alteration in functionally affected mutants. Reductions in EAE clinical scores were paralleled by reductions in demyelination, axonal loss, and astrogliosis. Receptor rescue and pharmacological experiments supported the loss of S1P 1 on astrocytes through functional antagonism by FTY720-P as a primary FTY720 mechanism. These data identify nonimmunological CNS mechanisms of FTY720 efficacy and implicate S1P signaling pathways within the CNS as targets for multiple sclerosis therapies.
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G protein-coupled receptor | knockout | lysophospholipid | neuroprotection M ultiple sclerosis is an autoimmune disorder characterized by CNS demyelination, inflammation, and neurodegeneration (1) . Current Food and Drug Administration (FDA)-approved therapies predominantly target immunological pathways through injectable agents. FTY720 (known clinically as fingolimod) is an oral drug that has shown efficacy in human multiple sclerosis clinical trials (2, 3) , and in September 2010, received FDA approval as an oral therapy for relapsing forms of multiple sclerosis. The actions of FTY720 seem to involve at least two, paradoxically, opposite sphingosine 1-phosphate (S1P) receptor mechanisms operating in the immune system: agonism and functional antagonism. FTY720 is phosphorylated in vivo to produce the active metabolite FTY720-P, which is a nonselective S1P receptor agonist for four of the five known S1P receptors (4-6), and can function as an agonist in vivo (7) . However, FTY720-P can also act as a functional antagonist, where bound S1P receptors are irreversibly internalized and degraded rather than recycled back to the cell surface as occurs with S1P ligands (8, 9) ; additionally, FTY720-P signaling may persist even after receptor internalization (10) . The biological locus responsible for FTY720 efficacy is believed to be immunological, whereby FTY720-P, acting through the receptor subtype known as S1P 1 , prevents lymphocyte egress from lymphoid organs, thus inhibiting CNS attack by pathogenic lymphocytes (4, (11) (12) (13) (14) (15) (16) (17) .
In addition to immunological mechanisms, data also exist for nonimmunological FTY720 mechanisms involving the CNS in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis. These include S1P receptor gene expression in the CNS (18, 19) , a discordance between peripheral blood lymphocyte (PBL) levels and FTY720 clinical efficacy in EAE-induced mice (12) , drug enrichment in the brain (19) , effects on cultured CNS cells (20) , sphingolipid CNS metabolic defects in some multiple sclerosis patients (21) , and expression of S1P receptors in multiple sclerosis brain lesions (22) . CNS mechanisms of FTY720, distinct from immune mechanisms, might represent a way to avoid liabilities of immunosuppression as well as potentially provide neuroprotection. However, no functional in vivo data currently exist to support an immunologically separate CNS mechanism for FTY720, and the identity of functionally involved cell types remains unknown. To address this issue, S1P 1 was genetically deleted from specific subsets of CNS cell types followed by EAE challenge combined with pharmacological, histological, cellular, and biochemical analyses. These studies implicate a primary CNS locus for FTY720 activity through S1P 1 in astrocytes.
Results
A genetic approach using an engineered, floxed S1P 1 allele (Fig.  S1 ) generated conditionally null mutants after crosses with previously established transgenic mice expressing different cell lineage promoters driving Cre recombinase for all CNS lineages (NestinCre) (23), neurons (Synapsin-Cre) (24) , or GFAP-expressing cell lineages, particularly in spinal cord white matter astrocytes (GFAPCre) (25, 26) . All mutants were back-crossed into C57BL/6J to allow assessment of these mutants when (i) challenged by EAE and (ii) therapeutically exposed to FTY720. Characterization of these conditional mutants showed the removal of S1P 1 from the targeted lineages (Fig. S1) .
Monophasic EAE was produced in mice by immunization with myelin oligodendrocyte glycoprotein (MOG). MOG-challenged WT (C57BL/6J) ( Fig. 1A and Fig. S2 A and B) or unrecombined control mice (S1pr1 loxP/loxP ) ( Fig. 1 C, E , and G) showed robust EAE clinical signs using conservative scoring criteria com-mencing 12-15 d after immunization, with clinical signs present through experiment termination (80 d) (Fig. S2B) . S1P 1 -dependent FTY720 efficacy was examined by assessing its known immunological effects in preventing lymphocyte egress from lymphoid compartments to produce PBL depletion (13, 14) . This effect has been proposed as the predominant mechanism of action for FTY720 (11, 16) . Consistent with prior reports, FTY720 administration after EAE disease onset reduced both clinical scores and PBL counts (11, 13, 27) (Fig. 1 A and B and Table S1), with both therapeutic and prophylactic efficacy (Fig. S2C) . S1P 1 expression has been reported on CNS neurons and glia (19, 28, 29) , the latter of which includes astrocytes (30) . To examine a possible CNS contribution to FTY720 efficacy through S1P 1 , EAE was induced in conditional null mutant mice where S1P 1 was eliminated from both neurons and glia (S1pr1 loxP/loxP ; Nestin-Cre) compared with unrecombined littermate controls (S1pr1 loxP/loxP ) followed by FTY720 administration ( Fig. 1 C and D and Table S1 ). All mice responded to EAE induction, with S1P 1 conditional mutants exhibiting a reduced level of disease severity (Fig. 1C) . PBL depletion after FTY720 administration was indistinguishable in controls vs. mutant mice (Fig. 1D and Table S1 ). If lymphocyte depletion was solely responsible for FTY720 efficacy, then EAE in S1P 1 null mutants should have been further reduced; however, this was not observed (Fig. 1C) . Rather, clinical scores were refractory to FTY720 treatment (Fig.  1C) , despite the maintained immunological effects on PBL depletion ( Fig. 1D and Table S1 ). Moreover, lymph node (LN) cells from S1pr1 loxP/loxP ; Nestin-Cre conditional mutants showed normal function as assessed by adoptive transfer experiments, where primed LN cells from EAE-induced unrecombined controls (S1pr1 loxP/loxP ) and conditional null mice induced host disease (Fig.  S2D ). These data indicate that immunological mechanisms are insufficient to fully account for the efficacy of FTY720 and support contributions by CNS S1P 1 signaling.
To identify involved CNS cell types, FTY720 efficacy was assessed using conditional null mutants for S1P 1 in neurons (S1pr1 loxP/loxP ; Synapsin-Cre) ( ; GFAP-Cre) (Fig. S1K ) challenged by EAE. Neuronal S1P 1 null mutants responded like littermate controls ( Fig.  1E ) and displayed normal lymphocyte depletion ( Fig. 1F and Table S1). In marked contrast, mice with conditional deletion of S1P 1 in GFAP-expressing cells resulted in a loss of response to FTY720 exposure ( Fig. 1G ), despite normal PBL depletion ( Fig. 1H and Table S1 ). Conditional mutants that were not treated with FTY720 exhibited the predicted pattern of stable disease progression, although clinical signs were attenuated when S1P 1 was deleted from astrocytes ( Fig. S2E) . These data identified a nonneuronal and likely astrocyte locus for S1P 1 signaling.
The Cre mice were chosen based on previously reported gene expression of S1P 1 in neurons and glia (19, 28, 29) and the proven specificity of the Cre-driving promoters used for removing genes from these cell types (23) (24) (25) (26) . To ascertain that S1P 1 removal was indeed occurring from embryonic precursor cells ( Fig. S1 ) and targeted adult cell populations, in situ hybridization analyses of control and conditional mutant brains and spinal cords were pursued (Fig. 2) . Prior reports had identified (Table S1 ). Clinical scores of A, C, E, and G were statistically analyzed using Mann-Whitney's test (Tables S2-S5 ).
Purkinje neurons of the cerebellum as a major brain locus for normal S1P 1 gene expression (28, 29) , and this general pattern was reproduced ( Fig. 2A) . However, assessment of each mutant genotype compared with controls ( Fig. 2 A-D) produced a surprising result, where neuronal deletion (by Synapsin-Cre) had no effect on cerebellar labeling, labeling was eliminated by panneuronal and glial (Nestin-Cre) as well as astrocyte-enriched deletion (GFAP-Cre). Higher magnification views of the cerebellar labeling revealed that Purkinje neurons were not labeled, whereas labeling occurred in surrounding cells that were consistent with being Bergmann glia, which are a population of cerebellar astrocytes (31) , an identity confirmed by double-labeling cells with GFAP (immunolabeling) and S1P 1 (in situ hybridization) ( Fig. 2A Inset) . Consistent with cerebellar astrocyte S1P 1 gene expression, in situ hybridization for S1P 1 was mostly eliminated throughout the neuraxis [brainstem (Fig. 2 E-H ) and spinal cord (Fig. 2 I-L) ] after conditional deletion by Nestin-or GFAP-Cre but remained at control levels after neuronal deletion using Synapsin-Cre. Astrocyte identification was supported by double labeling for S1P 1 and GFAP ( Fig. 2A Inset and M-O) . No obvious neuronal labeling was observed. Overall, these data effectively eliminate neuronal contributions of S1P 1 signaling to account for the observed functional alterations in EAE clinical scores of Nestin-or GFAP-Cre conditional mutants, and they identify GFAP-expressing astrocytes as both the major cell type expressing S1P 1 in the adult CNS and that which is affected by S1P 1 signaling produced during FTY720 exposure.
This astrocyte identification is consistent with astrogliosis, identified by GFAP immunolabeling (32, 33) , which occurs during both EAE (34) and multiple sclerosis (32, (35) (36) (37) . Notably, astrogliosis can precede clinical manifestations and immune cell infiltration in EAE (38) . Therefore, histological analyses on clinically defined CNS regions of the lumbar spinal cord were pursued. In normal EAE controls (Fig. 3 and Fig. S3 ), prominent astrogliosis was identified by increased GFAP immunoreactivity (Fig. 3B, GFAP and Fig. S3D ) along with increased spinal cord cell density, particularly in white matter tracts (Fig. 3B, DAPI and Fig. S3 B and C) , as well as increased numbers of CD11b-positive cells (microglia or macrophages) (Fig. S3E ) and lymphocytes (Fig. S3F) within lesion sites. Remarkably, FTY720 exposure before (Fig. 3E) or during (Fig. 3F and Fig. S3H ) EAE prevented or reduced astrogliosis accompanying increases in cell density as did specific deletion of S1P 1 by Nestin-or GFAP-Cre (Fig. 3D and Figs. S3 and S4A) . Accumulation of immune cells was also markedly reduced by genetic S1P 1 deletion (Fig. S3G ) or FTY720 exposure (Fig. S3H) . These data indicate that astrogliosis and some aspects of the immune response are promoted through astrocyte S1P 1 signaling and are reduced by genetic removal of S1P 1 from astrocytes as well as through FTY720 exposure.
Astrogliosis has also been reported after direct S1P injection into the CNS (39) or after spinal cord injury associated with increased S1P levels (40) . S1P levels were assessed in WT or NestinCre S1P 1 -conditional EAE spinal cords by HPLC/MS analysis. S1P content in EAE spinal cords was approximately twofold higher in WT EAE vs. WT naïve (non-EAE) mice (Fig. 3G) , consistent with an astrogliosis-S1P link. Notably, S1P levels were reduced in Nestin-Cre S1P 1 conditional null mutants (Fig. 3G) , suggesting links between S1P levels and astrocyte S1P 1 signaling.
Proinflammatory cytokines are a major factor in EAE and MS, particularly IL-1β, IL-6, and IL-17 (32, 41) . Expression levels for these cytokines were examined by assessing both protein (Fig.  3H) and mRNA (Fig. S3 I-K) levels. All were increased in WT mice during EAE (Fig. 3H and Fig. S3 I-K) but reduced by Nestin-Cre deletion of S1P 1 and by FTY720 administration (Fig.  3H and Fig. S3 I-K) . These data indicate that FTY720 exposure can regulate proinflammatory cytokine production during EAE through atrocyte S1P 1 signaling.
Demyelination and neurodegeneration are hallmarks of EAE and multiple sclerosis (1). Spinal cords from control and S1P 1 conditional null mutant EAE produced by Nestin-or GFAP-Cre (Fig. 3 and Fig. S4) were assessed by fluoromyelin staining and neurofilament immunolabeling; both mutations produced similar results. Levels of EAE-induced demyelination (Fig. 3I) and ax- Fig. 2 . S1P 1 gene expression and Cre-mediated conditional loss as detected by in situ hybridization identify astrocytes in the CNS. In situ hybridization shows S1pr1 expression (dark label) throughout the adult CNS (shown for cerebellum, brainstem, and spinal cord) in WT mice (A, E, and I) that is lost after conditional deletion in S1pr1 loxP/loxP ; Nestin-Cre (B, F, and J) and S1pr1 loxP/ loxP ; GFAP-Cre (C, G, and K) mice but not in S1pr1 loxP/loxP ; Synapsin-Cre (D, H, and L) mice. In WT mice, S1pr1 message is abundant in the Bergmann glia of the Purkinje layer in the cerebellum (A), which was confirmed by double labeling with a GFAP antibody (A Inset, red; P, Purkinje neuron) and not observed in other neuronal populations (G, granule neurons). In brainstem (E-H) and the white matter of spinal cord (I-L), S1pr1 message is present (arrows) in WT (I) and S1pr1 onal damage (Fig. 3J) were reduced in controls after FTY720 treatment ( Fig. 3 I and J) . Similarly, demyelination and axonal damage were also reduced in S1P 1 -deficient mice produced by Nestin-Cre or GFAP-Cre (Fig. 3 I and J and Fig. S4 B and C) . These histological data support protective effects of S1P 1 loss from astrocytes or FTY720 exposure.
To address S1P 1 function in EAE without potential complications of developmental perturbation produced by genetics, a pharmacological strategy was used with an S1P 1 -specific agonist, AUY954 (42), in WT EAE. Like FTY720, AUY954 administration during EAE also reduced the clinical severity of EAE (Fig. S5A) as well as astrogliosis (Fig. S5B) . These data independently support a role for S1P 1 that complements results obtained from both genetics and FTY720 administration.
The studies presented here identify S1P 1 signaling in astrocytes as a key mediator of FTY720 efficacy but also present a paradox: loss of S1P 1 signaling by S1P 1 deletion ameliorates EAE but so does exposure to S1P receptor agonists FTY720 (i.e., FTY720-P) (5) and AUY954 (42) . A single mechanism that accounts for these disparate activities has been reported for FTY720-P in the immune system, where it acts as a functional antagonist, doing so by removing receptors from the cell surface through irreversible internalization after receptor activation rather than the usual receptor recycling back to the cell surface that occurs with S1P itself (8, 9, 13, 43) . To assess this mechanism in astrocytes, primary astrocyte cultures were generated from S1P 1 -deficient mice (Fig. S6A ) and reconstituted by infection with an EGFP-tagged S1P 1 retrovirus. Brief exposure (0.5 h) of S1P 1 -EGFP-expressing astrocytes to either S1P (100 nM) or FTY720 (100 nM) induced rapid internalization of S1P 1 (Fig. 4A, 0.5 h) . S1P 1 was recycled to the cell surface in S1P-treated astrocytes (Fig. 4A, 2 h) . In sharp contrast, S1P 1 remained internalized in FTY720-treated astrocytes (Fig. 4A,  2 h ). FTY720 can be endogenously phosphorylated by sphingo- ; nestin-cre) EAE-induced (clinical score at examination = 0.5). (E) Control pretreated with FTY720 followed by EAE challenge (clinical score at examination = 0.5). (F) Control challenged with EAE followed by FTY720 (clinical score at examination = 1.5 before and = 0.5 after FTY720 administration) (Fig. S3 A-H) . (G) S1P levels in the lumbar spinal cord were increased after EAE challenge but reduced in S1P 1 conditional null mutants (S1pr1 loxP/loxP ; nestin-cre) as measured by HPLC/MS. Naïve (WT; n = 6), EAE (WT; n = 7; mean clinical score at examination = 2), and EAE (S1pr1 loxP/loxP ; nestin-cre; n = 5; mean clinical score at examination = 0.6). *P < 0.006 and **P < 0.0004 (t test). (H) Increased cytokine protein levels (IL-1β, IL-6, and IL-17) in the lumbar spinal cord after EAE challenge were reduced in S1P 1 conditional null mutants (S1pr1 loxP/loxP ; nestin-cre) or after FTY720 exposure as measured by ELISA. Naïve (WT; n = 8), EAE (WT; n = 7; mean clinical score at examination = 2), EAE (S1pr1 loxP/loxP ; nestin-cre; n = 5; mean clinical score at examination = 0.5), and EAE+FTY720 (WT; n = 8; mean clinical score at examination = 0.4). *P < 0.04, **P < 0.001 (vs. naïve), # P < 0.05, ## P < 0.006, and ### P < 0.001 (vs. EAE; t test) (Fig. S3 I-K) . (I) Demyelination was reduced by S1P 1 deletion (S1pr1 loxP/loxP ; nestin-cre) or FTY720 exposure as identified by fluoromyelin staining. (J) Axonal damage was reduced by S1P 1 deletion or FTY720 exposure as identified by antineurofilament immunolabeling. Use of an independent Cre driver that removed S1P 1 from astrocytes (S1pr1 loxP/loxP ; GFAP-cre) produced similar results (Fig. S4 ). (Scale bar: 100 μm.) sine kinase 2 (Sphk2) (6), which is expressed in these astrocytes (Fig. S6B) , consistent with S1P 1 effects activated by exogenously applied FTY720 or FTY720-P. As with FTY720, exposure to either FTY720-P or AUY954 also produced prolonged internalization of S1P 1 (Fig. 4A, 2 h ). These data were recapitulated in the astrocyte-like glioma cell line, C6, using S1P 1 overexpression (Fig. 4B ) that allowed prolonged examination during compound exposure compared with use of primary astrocytes. The sustained receptor internalization, consistent with functional antagonism, was maintained in the presence of FTY720, FTY720-P, and AUY954, similar to the results obtained in astrocytes.
Discussion
The aggregate results support functional antagonism of astrocyte S1P 1 rather than forms of agonism as the predominant receptor mechanism for FTY720 efficacy. Receptor internalization of FTY720-P-S1P 1 associated with a report of persistent agonism (10) is not likely to be relevant, because genetic as well as pharmacological loss of CNS S1P 1 signaling both reduced EAE clinical scores and histological sequelae, including astrogliosis, contrasting with S1P receptor agonism in the CNS that promotes astrogliosis (39, 40, 44) . Persistent S1P 1 signaling may be relevant to the actions of FTY720 on lymphocyte egress (10); however, the separation of immunological and CNS S1P 1 activities observed here supports functional antagonism within the CNS as the primary mechanism of action. It is notable that these distinguishable CNS effects may have particular relevance for primary progressive forms of multiple sclerosis that are refractory to immunomodulatory therapies (45) .
In the adult CNS, in situ hybridization and conditional deletion data support GFAP-expressing astrocytes as the major cell type influencing EAE-associated behavioral, histological, and biochemical endpoints. Reduced astrogliosis associated with S1P 1 loss along with reduced cytokine expression and S1P levels identify possible downstream mechanisms activated by S1P 1 loss or FTY720 exposure. Other nonmutually exclusive mechanisms downstream of S1P signaling in astrocytes include important astrocyte effects on the blood-brain barrier or possible neuroprotective actions, all of which deserve further investigation. S1P 1 has also been reported to be expressed by oligodendrocytes (46) , and under some conditions, neurons (19, 28, 29) . This deserves closer analysis in view of the clarified expression of S1P 1 on Bergmann glia rather than Purkinje neurons identified here, as well as non-CNS cell lineages that include microglia (47) and endothelial cells (9) , all of which may have roles at discrete phases of EAE or multiple sclerosis. The role of other expressed S1P receptor subtypes remains to be assessed.
In summary, this study identifies a nonimmunological CNS mechanism of action for FTY720 in EAE and likely, multiple sclerosis: loss of S1P 1 signaling from astrocytes (Fig. S7) . Genetic, in situ hybridization, and receptor internalization data identify astrocytes as the primary CNS cell type affected by S1P 1 modulation that is relevant to FTY720 efficacy. These effects seem to be largely distinct from the previously known effects of FTY720 on lymphocyte trafficking, results that may in part explain paradoxical human clinical data that showed increasing PBL depletion with increasing FTY720 dose (48) but unchanged or increasing efficacy in multiple sclerosis with decreasing FTY720 dose. The CNS activities observed here may also contribute to the as yet unexplained reductions in brain atrophy observed in human clinical trials (2, 3) that could hypothetically reflect CNS tissue preservation and neuroprotection. Thus, modulation of S1P receptor-influenced pathways within the CNS may offer strategies that could reduce or avoid immunosuppressive side effects common to current treatments and potentially provide neuroprotection towards the development of improved multiple sclerosis therapies.
Materials and Methods
EAE Induction and Drug Treatment. All animal protocols were approved by the Animal Research Committee (IACUC) of The Scripps Research Institute (TSRI) and conform to National Institutes of Health guidelines and public law. EAE was induced by MOG amino acid 35-55 (MEVGWYRSPFSRVVHLYRNGK, 98% purity; American Peptide) immunization in 7-to 9-wk-old female mice: WT mice (C57BL/6J) and conditional null mutants for S1P 1 in different CNS cell lineages, including S1pr1 loxP/loxP ; nestin-cre (S1P 1 deletion in all CNS cell lineages) (23), S1pr1 loxP/loxP ; synapsin-cre (S1P 1 deletion in neuronal lineages) (24) , and S1pr1 loxP/loxP ; GFAP-cre (S1P 1 deletion in astrocyte lineages) (25, 26) or littermate control mice (S1pr1 loxP/loxP ). For immunization, MOG was dissolved in water, and an emulsion was prepared in Complete Freund's Adjuvant (CFA). The emulsion of MOG (200 μg) in CFA was injected s.c., with an i.p. injection of Bordetella pertussis toxin (PTX; 400 ng PTX were injected into mice at days 0 and 2 after MOG/CFA injection), and then, mice were weighed and monitored daily. ; nestin-cre) were reconstituted by retroviral-mediated expression of a functional S1P 1 -EGFP fusion protein. Cells were treated with vehicle (0.1% BSA), S1P (100 nM), FTY720 (100 nM), FTY720-P (100 nM), or AUY954 (100 nM). Cells were assessed to identify receptor internalization (0.5 h) or possible receptor recycling to the cell surface (2 h) after ligand exposure compared with vehicle controls. At 0.5 h after vehicle exposure, native EGFP fluorescence identified cell surface labeling; all other panels used anti-GFP immunofluorescence, which produced punctate labeling. (B) Functional antagonism through receptor internalization is maintained over extended periods (0.5, 2, and 24 h) in C6 glioma cells overexpressing S1P 1 . At each time point, cells were fixed, and native EGFP fluorescence was detected. C6 glioma cells allowed extended examination periods of compound exposure compared with primary astrocytes. The sustained receptor internalization in both primary astrocytes and C6 cells is consistent with S1P 1 functional antagonism in the presence of FTY720, FTY720-P, and AUY954, contrasting with receptor recycling observed with S1P. Asterisks identify cytosolic locations, whereas arrows indicate the cell surface. (Scale bars: A, 10 μm; B, 20 μm.) μm) were fixed (10 min) in 4% paraformaldehyde (PFA), permeabilized in 0.5% Triton X-100, and blocked with 3% BSA. Tissue sections were labeled with primary antibodies or antisera; mouse anti-GFAP (1:1,000; Sigma) and rabbit antineurofilament 200 (1:200; Serotec) were used for detecting astrogliosis and axonal damage, respectively. To detect demyelination, tissue sections were stained with fluoroMyelin (1:300; Invitrogen). Sections were visualized directly or incubated with FITC-conjugated anti-IgG (1:2,000; Molecular Probes) and counterstained with DAPI (5 μg/mL). In situ hybridization for S1pr1 in the cerebellum, spinal cord, and brainstem of unrecombined control and various S1P 1 conditional null mutants used tissues sectioned at 20 μm and hybridized with an S1pr1-specific digoxigenin (DIG)-labeled antisense probe followed by colorimetric detection. Double labeling of tissue sections for immunohistochemistry used an anti-GFAP antibody and subsequent FITC-conjugated second antibody. Images were collected with an AxioCam digital camera (Zeiss) and prepared using Adobe Photoshop (version 8.0).
Measurements of S1P in Spinal Cord. Lumbar spinal cord was homogenized with ice-cold methanol (MeOH), centrifuged, and used for S1P extraction in the presence of 1 μM C17 S1P (Avanti Polar Lipids) as an internal standard. Samples were processed at the TSRI Center for Mass Spectrometry using an Agilent 6410 triple quad mass spectrometer coupled to an Agilent 1100 LC system. S1P levels were calculated compared with the internal standard, and the values were represented as picomoles per milligram of tissue.
Determination of Cytokine Levels by ELISA. Lumbar spinal cord protein samples were used to determine cytokine levels using ELISA kits: IL-1β (BD Pharmingen), IL-6 (Millipore), and IL-17 (R&D System). Protein levels of IL-1β and IL-17 were determined by absorbance at 450 nm and calculated based on appropriate standard curves. Protein levels of IL-6 were obtained from Millipore using Luminex.
Determination of S1P 1 Internalization and Recycling in Astrocytes. Primary astrocytes were isolated from cerebral cortices of S1P 1 conditional KO mice and retrovirally transduced with an S1P 1 -EGFP fusion construct. Cells were labeled with mouse anti-GFAP and rabbit anti-GFP and visualized with fluorescence-conjugated anti-IgG. S1P 1 localization in cells was determined by confocal microscopy equipped with the Fluoview program (Leica). The astrocyte cell line (C6 glioma cells) was similarly processed.
